Lexeo Therapeutics, Inc. Common Stock (LXEO) stock news · rev $654.0K
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
This LXEO news page leads with what Lexeo Therapeutics, Inc. Common Stock filed — not a scraped headline mill.
No cached 8-K sentence for LXEO yet. We will not pad this page with generic market recap.
Latest reported LXEO revenue for 2022-12-31 was $654.0K. Net income was $59.3M. LXEO currently screens at market cap $147.7M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the LXEO stock page; for the tape open the quote page.
LXEO stock news FAQ
What are LXEO's latest revenue and net income?
Latest cached Lexeo Therapeutics, Inc. Common Stock (LXEO) revenue for Dec 31, 2022 was $654.0K. Net income was $59.3M. Statements: https://lician.com/financials/lxeo
What is LXEO's market cap?
Lexeo Therapeutics, Inc. Common Stock (LXEO) market cap is $147.7M on the latest cached fundamentals snapshot.
What kind of company is LXEO?
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
Where is LXEO stock news listed?
Cached stock news for Lexeo Therapeutics, Inc. Common Stock (LXEO) is listed at https://lician.com/news/lxeo. Filings: https://lician.com/sec/lxeo
Not investment advice.